Literature DB >> 27083895

Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.

Rocco Totaro1, C Di Carmine2, A Splendiani3, S Torlone3, L Patriarca3, C Carrocci2, S Sciamanna2, C Marini4, A Carolei5.   

Abstract

Although tumefactive multiple sclerosis is a well recognized variant of multiple sclerosis, prognostic uncertainty still exists about long term prognosis. The aim of this study was to estimate the occurrence and long term outcome of tumefactive demyelinating lesions (TDLs) in a cohort of multiple sclerosis patients. We reviewed brain MRI of 443 patients referred to our MS clinic. All patients meeting the McDonald criteria for multiple sclerosis and showing at least one TDL were included. Kaplan-Meier estimates of disease-free survival in patient cohort were compared with control group without TDLs using a log-rank test. Seven cases with TDLs were identified (occurrence 1.58 %). Tumefactive demyelinating lesion recurrence was 16.6 %. Cumulative proportion of patients free from clinical relapse and from new T2 lesions was lower in the control group although not reaching statistical significance (30 vs 50 %; P = 0.666 and 21.7 vs 33.3 %; P = 0.761, respectively). Disability progression analysis showed a not significant trend towards lower probability of remaining progression free for TDL patients (50 vs 61 %; P = 0.295). Occurrence of tumefactive demyelinating lesions in our cohort was higher than those reported in other studies. Overall, TDLs were not predictive of poor outcome in terms of disability progression.

Entities:  

Keywords:  Long-term follow-up; Magnetic resonance imaging; Multiple sclerosis; Prevalence; Tumefactive demyelinating lesions

Mesh:

Year:  2016        PMID: 27083895     DOI: 10.1007/s10072-016-2558-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  27 in total

1.  Tumefactive multiple sclerosis plaque.

Authors:  S Khoshyomn; S P Braff; P L Penar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-07       Impact factor: 10.154

2.  Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.

Authors:  H S Malhotra; K K Jain; A Agarwal; M K Singh; S K Yadav; M Husain; N Krishnani; R K Gupta
Journal:  Mult Scler       Date:  2009-02       Impact factor: 6.312

3.  Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.

Authors:  Takao Kiriyama; Hiroshi Kataoka; Toshiaki Taoka; Yasuyo Tonomura; Mari Terashima; Masami Morikawa; Emi Tanizawa; Makoto Kawahara; Yoshiko Furiya; Kazuma Sugie; Kimihiko Kichikawa; Satoshi Ueno
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

4.  Marburg's variant of multiple sclerosis correlates with a less compact structure of myelin basic protein.

Authors:  D R Beniac; D D Wood; N Palaniyar; F P Ottensmeyer; M A Moscarello; G Harauz
Journal:  Mol Cell Biol Res Commun       Date:  1999-04

5.  Tumefactive multiple sclerosis: an uncommon diagnostic challenge.

Authors:  Martha A Kaeser; Frank Scali; Frank P Lanzisera; Glenn A Bub; Norman W Kettner
Journal:  J Chiropr Med       Date:  2010-10-08

6.  Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients.

Authors:  J J Kepes
Journal:  Ann Neurol       Date:  1993-01       Impact factor: 10.422

Review 7.  Tumefactive demyelination: an approach to diagnosis and management.

Authors:  Todd A Hardy; Jeremy Chataway
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-01-19       Impact factor: 10.154

8.  Multiple sclerosis mimicking primary brain tumor.

Authors:  S B Hunter; W E Ballinger; J J Rubin
Journal:  Arch Pathol Lab Med       Date:  1987-05       Impact factor: 5.534

9.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.

Authors:  C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück
Journal:  Brain       Date:  2008-06-05       Impact factor: 13.501

10.  Open-ring enhancement in pseudotumoral multiple sclerosis: important radiological aspect.

Authors:  Frederico Carvalho de Medeiros; Lucas Alverne Freitas de Albuquerque; Jose Eymard Homem Pittella; Renata Brant de Souza; Antonio Pereira Gomes Neto; Paulo Pereira Christo
Journal:  Case Rep Neurol Med       Date:  2014-04-15
View more
  3 in total

1.  Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients.

Authors:  Alessandra Splendiani; Marco Perri; Claudia Marsecano; Valentina Vellucci; Giulia Michelini; Antonio Barile; Ernesto Di Cesare
Journal:  Radiol Med       Date:  2017-09-27       Impact factor: 3.469

2.  Is size an essential criterion to define tumefactive plaque? MR features and clinical correlation in multiple sclerosis.

Authors:  Lucia Patriarca; Silvia Torlone; Fabiana Ferrari; Caterina Di Carmine; Rocco Totaro; Ernesto di Cesare; Alessandra Splendiani
Journal:  Neuroradiol J       Date:  2016-08-16

Review 3.  Effect of exercise therapy on quality of life of patients with multiple sclerosis in Iran: a systematic review and meta-analysis.

Authors:  Abolhassan Afkar; Asieh Ashouri; Marjan Rahmani; Abdolhosein Emami Sigaroudi
Journal:  Neurol Sci       Date:  2017-07-07       Impact factor: 3.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.